Patheon Still Considering Terms Of Takeover

Canadian drugmaker Patheon has stated that it will continue to explore the Lonza bid of US$3.55 per share, or US$460mn, for 67% of the firm during the exclusive negotiation period through September 2009.

To read the full article, please choose one of the following options: